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5-HT1BR INVOLVEMENT IN BEHAVIORAL EFFECTS OF FLX
Abstract
Selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine (Prozac) are the most
commonly prescribed treatments for depression. Although efficacious for symptoms such as a
depressed mood, SSRIs do not alleviate symptoms of amotivation, anergia, and fatigue.
Furthermore, in clinical and preclinical studies, SSRIs have been shown to exacerbate
motivational impairments and general fatigue. It is likely that fluoxetine-induced dysfunctions
are due to overstimulation of one or more 5-HT receptors, with one possible candidate being the
5-HT1B receptor. Therefore, the aim of the study was to evaluate the role of 5-HT1BRs in
fluoxetine-induced amotivation using a rodent behavioral model of effort-based decisionmaking. For these experiments, the selective 5-HT1BR antagonist, NAS-181, was coadministered with fluoxetine to determine if fluoxetine-induced suppression of high effort
behavior could be attenuated. NAS-181 partially reversed the effects of fluoxetine in rats that
showed a greater fluoxetine-induced behavioral suppression in our task, which was not found in
rats with low fluoxetine-induced suppression. Future directions involve intracranial
administration and investigation of the role of other 5-HTRs on effort-related behaviors.
Keywords: depression, 5-HT1BR, motivational impairment, SSRI

2

5-HT1BR INVOLVEMENT IN BEHAVIORAL EFFECTS OF FLX

3

Investigating the neurobiology of motivational deficiencies in Major Depressive Disorder:
5-HT1B receptor involvement in behavioral effects of fluoxetine (Prozac)
Major depressive disorder (MDD) is a common psychiatric disorder, with roughly 7.6%
of Americans over the age of 12 suffering from MDD in a given 2-week period15. Not only is
MDD highly prevalent, but it is also incredibly debilitating, with the World Health Organization
ranking it as the leading cause of disease burden across both low and high income countries22.
Motivational symptoms in particular (e.g. psychomotor retardation, lack of energy, low exertion
of effort, fatigue) severely impair important aspects of a patient’s life and tend to be the most
treatment resistant aspects of MDD18. Because of its prevalence and severity as a worldwide
health concern, the need for effective treatments is extremely great.
For these reasons, considerable work has focused on developing a greater understanding
of the neurobiology of the motivational aspects of MDD, with a particular focus on preclinical
studies of potential treatments that affect effort-related decision-making. Over the past few
decades, behaviorally validated rodent models of effort-related motivational impairments have
been developed. These assays quantify effort exertion in animals by offering a choice between
obtaining a highly preferred reward through high exertion of effort behaviors (e.g. lever pressing
or barrier climbing) vs. low-effort options leading to less preferred rewards18. In rodents,
conditions linked to depression (e.g. stress, inflammatory, or pharmacological challenge) can
induce a low-effort bias, which is consistent with the results of human studies on effort-based
choice in MDD patients7,18. For example, the vesicular monoamine transport type 2 (VMAT-2)
inhibitor tetrabenazine (TBZ), which causes depressive symptoms in people, can produce a loweffort decision bias in rats that can be reversed by drugs that can improve motivational symptoms
in people, such as bupropion and methylphenidate13. Bupropion and methylphenidate inhibit the
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reuptake of catecholamines (dopamine (DA) and norepinephrine), which causes an increase in
the extracellular concentrations of these neurotransmitters13. These DAergic mechanisms appear
to be crucial in determining the ability of a drug to improve effort-related processes, which is
consistent with recent clinical studies focusing on the importance of nucleus accumbens DA for
regulating motivational function18,23,25. However, DA does not regulate these effort-related
functions alone, and there is evidence of interactions between DA and several other
neurotransmitters, including GABA, serotonin (5-HT), and adenosine.
To illustrate how other neurotransmitters can exhibit influences on DAergic actions, some
of our previous research in the Salamone lab has focused upon interactions between DA and
adenosine17. Adenosine A2A receptors are co-localized with DA D2 receptors in DA-rich striatal
areas of the brain (such as neostriatum and nucleus accumbens) and have been found to influence
the post-synaptic effects of DA14,19. Moreover, many studies have demonstrated that by
inhibiting adenosine A2A receptors, the motivational effects of DA antagonists and depletions can
be reversed5,14,21. Preladenant (PLD), an adenosine A2A receptor antagonist, was initially
developed as a possible treatment for Parkinson’s Disease and is much more selective
(about 1000-fold more selective) for the A2a receptor compared to other adenosine receptors1,8.
Therefore, to evaluate the potential of PLD for the treatment of MDD in a previous study, we
used a concurrent operant choice procedure and were able to demonstrate that PLD can reverse
the effort-related impairment induced by TBZ17.
Current research in the Salamone lab also is focused on the role of 5-HT, and interactions
between DA and 5-HT, in animal models of depression and other psychiatric disorders. The most
commonly prescribed antidepressants are selective serotonin reuptake inhibitors (SSRIs) such as
fluoxetine (Prozac)18. While these drugs can treat a variety of depressive symptoms (e.g. mood,
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rumination, and anxiety), effort-related motivational symptoms tend to be much more resistant to
treatment with SSRIs6,18. In rat studies of effort-related decision making, the SSRIs fluoxetine
and citalopram failed to reverse the effort-related effects of TBZ6,23,25. Not only has fluoxetine
been found to be relatively ineffective in reversing motivational deficiencies in both clinical
studies and preclinical rodent models, but it has even been found to exacerbate motivational
deficits in rats and humans when administered alone6,18,23,24,25. Fluoxetine was recently shown to
decrease selection of high-effort lever pressing activity on a progressive ratio/chow feeding
choice task (PROG), a procedure in which the lever pressing work requirement progressively
increases causing rats to eventually switch from high-effort lever pressing to the low effort
alternative24. In addition to reducing selection of high-effort behavior in rats, fluoxetine also
decreased extracellular DA in the nucleus accumbens24. As the mechanism of action of SSRIs
involves elevating extracellular levels of serotonin (5-HT) by blocking 5-HT reuptake, it is likely
that the motivational dysfunctions induced by fluoxetine are due to an overstimulation of one or
more 5-HT receptors. Supporting this, a recent study determined that enhancing 5-HT
transmission from the dorsal raphe nucleus (DRN) to the VTA results in a decrease in striatal
DA2.
There are several subtypes of 5-HT receptors in the brain (i.e., 5-HT1-7, with additional
subtypes within some of these families of receptors). However, despite the direct localization of
5-HT2 family receptors on DA neurons in the mesolimbic pathway, previous findings have
obtained signify that the behavioral functions of 5-HT2A and 5-HT2C receptors do not appear to
be involved in fluoxetine induced amotivation (Rotolo et al., in preparation). Therefore, it is
critical to shift our focus to a broader range of 5-HT receptors in order to individually
characterize their functions and possible contributions to effort-related behavior.
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The 5-HT1B receptor has been implicated in various behavioral effects in rodent models.
Nautiyal et al. have shown that 5-HT1B receptors in the ventral tegmental area (VTA) appear to
play a role in the modulation of impulsive behaviors, and evidence indicates that this is possibly
due to actions on the mesolimbic DA neurons that originate in VTA and project to the nucleus
accumbens11. Therefore, it is possible that 5-HT1B receptors may be able to mediate aspects of
motivation via the same interactions. Consistent with this idea, 5-HT1B autoreceptors are
localized in the DRN, which has projections to the VTA and has been implicated in the
regulation of striatal DA2,9. Furthermore, knockout mice for 5-HT1B autoreceptors have
demonstrated a reduction in depressive and anxiety-like behavior12. For these reasons, there is
particular interest in the 5-HT1B receptor when considering aspects of motivated behavior.
Therefore, the aim of this study was to determine whether a 5-HT1BR antagonist, NAS-181
(NAS), could reverse the low effort bias induced by fluoxetine in a rodent model which would
implicate a role for 5-HT1B receptors in the mechanisms of fluoxetine.

Methods
Animals.
11 male Sprague Dawley rats with no prior drug experience were obtained from Harlan
Laboratories, Indianapolis, IN, USA, initially weighing about 279-299 g. Rats were pair housed
in a colony maintained at 23°C with a 12 hr light/dark cycle (lights on 07:00). Rats were food
restricted to 85% of their free-feeding body weight for initial training, and allowed modest
growth during the study. Water access in the home cages was unrestricted. All animal procedures
have been approved by the University of Connecticut Institutional Animal Care and Use
Committee (Salamone Lab Protocol: A17017).
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Behavioral Task.
The experiment used a fixed ratio of 5 (FR5)/chow feeding choice task to assess effortrelated decision making. With this task, rats are given the choice between working for preferred
high carbohydrate food pellets (45 mg; Bio-Serv, Frenchtown, NJ) by lever pressing on a FR5
schedule (5 presses delivers one pellet) vs. approach and consumption of the less preferred
standard lab chow. Behavioral testing sessions (30 min session, 5 days/week) were conducted in
Med Associates operant chambers during the light part of the light/dark cycle at the same time
each day. Rats were trained initially to lever press for pellets on a FR1 schedule for one week,
after which they were switched to an FR5 schedule for roughly four weeks. After reaching stable
baseline lever presses per session, concurrently available laboratory chow was introduced to the
operant chambers for the FR5/chow feeding choice task.
Drugs.
Subcutaneous injections of the selective 5-HT1B antagonist NAS-181 (Tocris Bioscience),
co-administered with fluoxetine (FLX), was used to determine if the 5-HT1B receptor is
responsible for the reduced selection of high-effort FR5 lever pressing induced by FLX. FLX
was dissolved in 0.9% saline which was also used as the vehicle control, and was administered at
12.5 mg/kg 90 minutes before testing. NAS-181 (1.0-8.0 mg/kg) or its 0.9% saline vehicle
control was administered 50 minutes before testing. A repeated measures design was used,
meaning each animal received all combinations of drug treatments once per week in a randomly
varied order. The drug treatments were: FLX vehicle + NAS-181 vehicle (VEH/VEH), 12.5
mg/kg FLX + NAS-181 vehicle (FLX/VEH), 12.5 mg/kg FLX + 1.0 mg/kg NAS-181
(FLX/NAS 1), 12.5 mg/kg FLX + 2.0 mg/kg NAS-181 (FLX/NAS 2), 12.5 mg/kg FLX + 4.0
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mg/kg NAS-181 (FLX/NAS 4), and 12.5 mg/kg FLX + 8.0 mg/kg NAS-181 (FLX/NAS 8) (6
total treatments).
Data Analysis.
Repeated measures analysis of variance (ANOVA) was calculated using SPSS. For some
analyses, and rats were split into groups based on the degree of suppression induced by FLX. To
determine sources of significant effects we used non-orthogonal planned comparisons using the
overall error term from each analysis. Power analysis was also used to determine the group size.
Results
To assess the possible role of 5-HT1B receptors on motivational impairments associated
with FLX, we investigated the behavioral effects of NAS coadministration with FLX on lever
pressing and chow consumption in a FR5/chow concurrent choice task. Analysis of chow intake
revealed no significant differences between any of the treatments (data not shown). Initial
analysis of lever pressing demonstrated a significant reduction in behavior upon FLX/VEH
administration, however coadministration of FLX with various NAS doses appeared to produce
no significant differences compared to FLX/VEH (data not shown). However, we did observe
great variation regarding the magnitude of FLX suppression between individual subjects.
Therefore, we used a criterion of 75% suppression of lever pressing from baseline to
separate those experiencing a large amount of FLX behavioral suppression from those that only
experience moderate to low changes in behavior. The resulting “high FLX suppression” (n=6)
and “low FLX suppression” (n=5) cohorts each had less variation of lever pressing suppression
than when the two different groups were treated as a whole. To illustrate how fundamentally
different these two cohorts were regarding their behavioral suppression, the high FLX
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suppression cohort averaged a FLX-induced suppression in pressing from vehicle that was
upwards of 90% whereas that of the low suppression cohort fell short of 45%.
Proceeding with our planned analyses, instead treating the two groups as the distinct
groups they are, revealed two contradicting behavioral profiles (Figure 1). While both cohorts
displayed significance in FLX/VEH suppression from VEH/VEH baseline lever pressing
[F(1,25)=33.255 p<0.01; F(1, 20)=7.125 p<0.025], NAS administration with the high
suppression cohort produced a partial but significant reversal of the pharmacological challenge
induced by FLX [F(1,25)=4.580, p<0.05] (Figure 1A). NAS administration for the low
suppression cohort, however, resulted in a significant attenuation of lever pressing
[F(1,20)=5.328, p<0.05] (Figure 1B). Additionally, the quadratic trend is significant when
assessing the interaction between the two groups [F(1,9)=6.921 (p<0.05, p=0.027)]. The chow
intake once again displayed no significant differences across treatment groups in either the high
suppression or low suppression cohorts (data not shown).

Discussion
The goal of the study was to determine if 5-HT1BR are implicated in the mechanisms of
FLX-induced amotivation. Through 5-HT1BR antagonism, we were able to obtain a partial
restoration of lever pressing behavior from the effects of FLX in a subset of rats, which signifies
that 5-HT1BR do appear to play at least a partial role in the impairments of FLX. As individual
variance in the magnitude of FLX-induced amotivation actually appears to be predictive of the
behavioral effects of serotonin antagonism, we also looked at previous results we had obtained
from similar studies investigating 5-HT2 family antagonists. However, utilizing the same method
of cohort separation as well as the same criterion, we were unable to observe the same
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phenomenon. This supports the idea that the effect we identified in this experiment truly is
unique to the 5-HT1BR.
Although we obtained no compensatory increase in chow intake due to decreased lever
pressing, this is consistent with our previous studies using FLX and is thought to occur due to the
appetite suppressant effects of the drug. Furthermore, the behavioral change due to FLX
administration does appear to be motivational in nature rather than appetitive as experiments our
lab has conducted using nonfood reinforces also see a shift to a low effort preference as well.
It is possible that the behavioral differences observed between these two cohorts may be
indicative of differences in receptor tone. Therefore, the proposed biological basis underlying
FLX-induced amotivation seen in patients may also involve differential expression patterns of
the 5-HT1BR. Further studies are required to validate this prediction however. Namely,
histological analysis of 5-HT1BR expression throughout the DRN or possibly neurons in the VTA.
To further understand whether 5-HT1BRs specifically in the DRN and VTA are involved
in FLX-induced motivational suppression, it would be important to conduct further
investigations utilizing intracranial NAS-181 administration directly to these areas. This could
potentially reveal a greater behavioral effect than those seen with systemic administration as
there would be less recruitment of extraneous serotonergic systems. Alternatively, if no effect is
seen through the involvement of these areas alone, alternative areas such as the frontal cortex
may be more greatly involved than we initially thought.
We are currently investigating whether NAS-181 administration alone may be increasing
high effort behavior using a progressive ratio choice study and also plan to evaluate whether 5HT1BR antagonism may be resulting in changes of extracellular DA concentrations in the NAc.
These studies will involve using microdialysis methods and high performance liquid
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chromatography with electrochemical detection with the ultimate goal to understand if 5-HT1BR
mediates the behavioral outcomes we observed through DAergic actions. If not, 5-HT1BR also
are known to serve as heteroreceptors regulating transmission of acetylcholine, glutamate,
norepinephrine and GABA, any of which may also be involved in this behavioral outcome9. In
this vein, we also have underway a study coadministering FLX with PCPA, a tryptophan
hydroxylase inhibitor which would downregulate 5-HT synthesis overall. This would provide
some insight as to whether 5-HT truly is the primary mediator of FLX-induced amotivation, and
whether or not the motivational impairment effects seen as a result of FLX administration are
possible to reverse through pharmacological mechanisms.
Additionally, future directions involve evaluating possible combined effects between the
5-HT1BR as it interacts with others. In particular, systemic co-administration of 5-HT1B and 5HT1C receptor agonists has been shown to decrease firing of DAergic neurons in the VTA with a
greater extent than agonism of 5-HT1BR alone16. It is possible that the reverse could be true as
well, with 5-HT1C and 5-HT1B antagonism potentially resulting in a greater if not full reversal of
the FLX-induced behavioral challenge. The determination of involvement of particular 5-HT
receptors in mediating motivated behaviors has proven to be difficult, however, further research
will contribute to the discovery of possible therapeutic mechanisms to treat the most debilitating
symptoms of MDD.
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Figure 1
A

B

Figure 1. Mean (±SEM) number of lever presses for the high FLX suppression (1A) and low
FLX suppression (1B) cohorts following coadministration of FLX along with NAS, a selective 5HT1BR antagonist in a FR5/chow behavioral choice task. Doses of NAS ranged from 1.0 mg/kg
to 8 mg/kg. 1A, FLX suppression paired comparisons from VEH/VEH to FLX/VEH was
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significant [# denotes F(1,25)=33.255 p<0.01] as was the partial reversal from FLX/VEH to
FLX/NAS2 (denoted by *) [F=4.580 p<0.05]. 1B, FLX suppression paired comparisons from
VEH/VEH to FLX/VEH was significant [# denotes F(1,20)=7.125 p<0.025] as was the
attenuation from FLX/VEH to FLX/NAS8 (denoted by *) [F(1,20)=5.328 p<0.05]. The quadratic
trend in the high FLX suppression cohort is significant when assessing the interaction between
the two groups [F(1,9)=6.921 p<0.05, p=0.027].

